These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28493307)

  • 1. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.
    Lv JW; Chen YP; Huang XD; Zhou GQ; Chen L; Li WF; Tang LL; Mao YP; Guo Y; Xu RH; Ma J; Sun Y
    Cancer; 2017 Sep; 123(18):3540-3549. PubMed ID: 28493307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China.
    Liu X; Li X; Jiang N; Lei Y; Tang LL; Chen L; Zhou GQ; Sun Y; Yue D; Guo R; Mao YP; Li WF; Liu LZ; Tian L; Lin AH; Ma J
    Cancer; 2014 Jan; 120(1):68-76. PubMed ID: 24114075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.
    Hwang JP; Suarez-Almazor ME; Cantor SB; Barbo A; Lin HY; Ahmed S; Chavez-MacGregor M; Donato-Santana C; Eng C; Ferrajoli A; Fisch MJ; McLaughlin P; Simon GR; Rondon G; Shpall EJ; Lok AS
    Cancer; 2017 Sep; 123(17):3367-3376. PubMed ID: 28518219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area.
    Hsu PI; Lai KH; Cheng JS; Kao SS; Li YR; Sun WC; Chen WC; Lin KH; Shin CA; Chiang PH; Li YD; Ou WT; Chen HC; Yu HC
    Hepatology; 2015 Aug; 62(2):387-96. PubMed ID: 26041578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine.
    Yeo W; Hui EP; Chan AT; Ho WM; Lam KC; Chan PK; Mok TS; Lee JJ; Mo FK; Johnson PJ
    Am J Clin Oncol; 2005 Aug; 28(4):379-84. PubMed ID: 16062080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study.
    Dan JQ; Zhang YJ; Huang JT; Chen MS; Gao HJ; Peng ZW; Xu L; Lau WY
    Eur J Surg Oncol; 2013 Aug; 39(8):865-72. PubMed ID: 23597497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.
    Chen CY; Tien FM; Cheng A; Huang SY; Chou WC; Yao M; Tang JL; Tien HF; Sheng WH
    BMC Gastroenterol; 2018 Jan; 18(1):6. PubMed ID: 29310589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.
    Paul S; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
    Ann Intern Med; 2016 Jan; 164(1):30-40. PubMed ID: 26595058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of hepatitis B virus screening and antiviral prophylaxis with adverse liver outcomes in Chinese cancer patients undergoing chemotherapy: A retrospective study.
    He LY; Wang YL; Tian X; Chen WQ
    Medicine (Baltimore); 2020 Apr; 99(14):e19647. PubMed ID: 32243396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013.
    Zhang LL; Li GH; Li YY; Qi ZY; Lin AH; Sun Y
    Cancer Res Treat; 2019 Jul; 51(3):982-991. PubMed ID: 30309219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
    Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
    Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.
    Tang LQ; Li CF; Li J; Chen WH; Chen QY; Yuan LX; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Zhang L; Guo SS; Liu LT; Guo L; Wu YS; Luo DH; Huang PY; Mo HY; Xiang YQ; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Cao KJ; Qian CN; Guo X; Zeng YX; Mai HQ; Zeng MS
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma.
    Huang L; Li J; Lau WY; Yan J; Zhou F; Liu C; Zhang X; Shen J; Wu M; Yan Y
    J Gastroenterol Hepatol; 2012 Jan; 27(1):158-64. PubMed ID: 21871026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.